Patents by Inventor Laurent Creancier

Laurent Creancier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Flavagline derivatives
    Patent number: 10519125
    Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 31, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric Marion, El Bachir Kaloun, Frédéric Lieby-Muller, Michel Perez, Jean-Philippe Annereau, Laurent Creancier
  • Flavagline derivatives
    Patent number: 10047064
    Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: August 14, 2018
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric Marion, El Bachir Kaloun, Frédéric Lieby-Muller, Michel Perez, Jean-Philippe Annereau, Laurent Creancier
  • FLAVAGLINE DERIVATIVES
    Publication number: 20180086729
    Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 29, 2018
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric MARION, El Bachir KALOUN, Frédéric LIEBY-MULLER, Michel PEREZ, Jean-Philippe ANNEREAU, Laurent CREANCIER
  • FLAVAGLINE DERIVATIVES
    Publication number: 20170137400
    Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
    Type: Application
    Filed: July 6, 2015
    Publication date: May 18, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric MARION, El Bachir KALOUN, Frédéric LIEBY-MULLER, Michel PEREZ, Jean-Philippe ANNEREAU, Laurent CREANCIER
  • Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk
    Patent number: 9428510
    Abstract: The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: August 30, 2016
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Anna Kruczynski, Laurent Creancier, El Bachir Kaloun, Karim Bedjeguelal, Rémi Rabot
  • DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk
    Publication number: 20150266880
    Abstract: The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.
    Type: Application
    Filed: July 29, 2013
    Publication date: September 24, 2015
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Anna Kruczynski, Laurent Creancier, El Bachir Kaloun, Karim Bedjeguelal, Rémi Rabot